Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Article

sustainable development goals

publication date

  • June 10, 2017

webpage

published in

start page

  • 2287

end page

  • 2303

volume

  • 389

issue

  • 10086